Sjögren’s Disease – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Sjögren’s Disease Emerging Therapy and TPP Insights

Thelansis’s “Sjögren’s Disease Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Sjögren’s Disease Overview

Sjögren’s disease is a systemic autoimmune disorder characterized by immune dysfunction of exocrine glands, causing dry eyes, dry mouth, fatigue, pain, and, in some patients, systemic organ involvement. Although glandular inflammation and B-cell hyperactivity are central features, manifestations vary. Historically, treatment has focused on symptomatic therapies and immunomodulation for active systemic disease, with no disease-specific therapy approved. This creates an unmet need for treatments that control systemic disease and reduce patient burden. The landscape is shifting toward targeted immunomodulation, including B-cell/BAFF-R pathways, CD40L blockade, and emerging kinase approaches. Ianalumab, a BAFF-R-directed B-cell-depleting antibody, achieved positive Phase 3 results and received FDA Breakthrough Therapy and Priority Review designations in 2026, while dazodalibep, a CD40L inhibitor, also reported positive Phase 3 results. These advances support targeted treatment development.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)